New synthetic cannabinoids and the potential for cardiac arrhythmia risk

Jules C Hancox*, Caroline S. Copeland, Stephen C Harmer, Graeme Henderson

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

1 Citation (Scopus)
57 Downloads (Pure)

Abstract

Synthetic cannabinoid receptor agonists (SCRAs) have been associated with QT interval prolongation. Limited preclinical information on SCRA effects on cardiac electrogenesis results from the rapid emergence of new compounds and restricted research availability. We used two machine-learning-based tools to evaluate seven novel SCRAs' interaction potential with the hERG potassium channel, an important drug antitarget. Five SCRAs were predicted to have the ability to block the hERG channel by both prediction tools; ADB-FUBIATA was predicted to be a strong hERG blocker. ADB-5Br-INACA and ADB-4en-PINACA showed varied predictions. These findings highlight potentially proarrhythmic hERG block by novel SCRAs, necessitating detailed safety evaluations.
Original languageEnglish
Article number100049
JournalJournal of Molecular and Cellular Cardiology
Volume6
Early online date16 Sept 2023
DOIs
Publication statusPublished - 1 Dec 2023

Fingerprint

Dive into the research topics of 'New synthetic cannabinoids and the potential for cardiac arrhythmia risk'. Together they form a unique fingerprint.

Cite this